Further investigation revealed that nuciferine and siRNA PASK could respectively regulate the expression of target genes involved in lipogenesis and inflammation, suggesting that nuciferine may be a potential therapeutic treatment for NAFLD. The gene discussed is PASK; the disease is metabolic dysfunction-associated steatotic liver disease.